-
1.发明授权Use of methylnaltrexone and related compounds to treat chronic opioid use side affects 有权使用甲基纳曲酮及其相关化合物治疗慢性阿片类药物使用方面的影响公开(公告)号：US06559158B1
公开(公告)日：2003-05-06
申请号：US09669358
申请日：2000-09-26
IPC分类号： A61K31485
CPC分类号： A61K31/485
摘要： A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
摘要翻译： 一种在长期摄取阿片样物质的患者中预防或治疗阿片样物质诱导的副作用的方法，所述方法包括以足以防止或治疗患者副作用的量施用去甲吗啡酮的季衍生物， 不足以治疗没有长期服用阿片类药物的相同阿片样物质诱导的副作用的患者。
-
2.发明申请公开(公告)号：US20120277260A1
公开(公告)日：2012-11-01
申请号：US13533578
申请日：2012-06-26
IPC分类号： A61K31/485 , A61P1/00
CPC分类号： A61K31/485
摘要： A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
-
公开(公告)号：US06608075B2
公开(公告)日：2003-08-19
申请号：US09862169
申请日：2001-05-21
IPC分类号： A61K31485
CPC分类号： A61K31/485
摘要： A method for preventing or treating opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
摘要翻译： 一种预防或治疗阿片样物质诱导胃肠蠕动变化的方法。 所述方法包括在施用阿片样物质之前或在施用阿片样物质引起的副作用开始之后向患者施用甲氧基纳曲酮或其他季戊四醇衍生物，其中所述甲基纳曲酮或季衍生物以肠溶包衣形式口服给药 。
-
公开(公告)号：US06274591B1
公开(公告)日：2001-08-14
申请号：US09120703
申请日：1998-07-22
IPC分类号： A61K31448
CPC分类号： A61K31/485
摘要： A method for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
摘要翻译： 公开了一种预防或治疗阿片样物质诱导的副作用，抑制胃肠蠕动的方法。 所述方法包括在施用阿片样物质之前或在施用阿片样物质引起的副作用开始之后向患者施用甲氧基纳曲酮或其他季戊四醇衍生物，其中所述甲基纳曲酮或季衍生物以肠溶包衣形式口服给药 。
-
5.发明申请USE OF METHYLNALTREXONE AND RELATED COMPOUND TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS 审中-公开甲基放射线及其相关化合物在慢性阿片类药物中的使用公开(公告)号：US20100087472A1
公开(公告)日：2010-04-08
申请号：US12495324
申请日：2009-06-30
IPC分类号： A61K31/485 , A61P1/10
CPC分类号： A61K31/485
摘要： A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
摘要翻译： 一种在慢性服用阿片样物质的患者中预防或治疗便秘的方法，所述方法包括以足以防止或治疗患者副作用的量施用去甲吗啡酮的季衍生物，但是哪种量不足以治疗 具有相同阿片类药物副作用的患者，没有长期服用阿片样物质。
-
6.发明申请USE OF METHYLNALTREXONE AND RELATED COMPOUNDS FOR TREATMENT OF GASTROINTESTINAL DYSFUNCTION INDUCED BY ENDOGENOUS OPIOIDS 审中-公开使用甲基内酯和相关化合物治疗由内源性OPIOIDS诱导的胃肠功能异常公开(公告)号：US20090312359A1
公开(公告)日：2009-12-17
申请号：US12333912
申请日：2008-12-12
IPC分类号： A61K31/485
CPC分类号： A61K31/485
摘要： A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.
摘要翻译： 一种在慢性服用阿片样物质的患者中预防或治疗由内源性阿片样物质引起的胃肠功能障碍和便秘的方法。 所述方法包括最优选通过肠胃外，肌内，静脉内或口服途径施用甲氧基纳曲酮或其它去甲吗啡酮的季衍生物。
-
公开(公告)号：US5972954A
公开(公告)日：1999-10-26
申请号：US962742
申请日：1997-11-03
IPC分类号： A61K31/485
CPC分类号： A61K31/485
摘要： A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.
摘要翻译： 一种预防或治疗阿片样物质诱发的副作用的方法，包括躁动症，瘙痒和尿潴留以及非阿片样物质诱导的胃肠蠕动变化。 所述方法包括在施用阿片样物质之前或在施用阿片样物质引起的副作用开始之后向患者施用甲氧基纳曲酮或其他季戊四醇衍生物，其中所述甲基纳曲酮或季衍生物通过选自 静脉内，肌肉内，经粘膜，透皮和口服给药组，优选以肠溶包衣形式口服给药。
-
公开(公告)号：US20050048117A1
公开(公告)日：2005-03-03
申请号：US10962729
申请日：2004-10-12
申请人： Joseph Foss , Michael Roizen , Jonathan Moss , Chun-Su Yuan , William Drell
发明人： Joseph Foss , Michael Roizen , Jonathan Moss , Chun-Su Yuan , William Drell
IPC分类号： A61K31/485 , A61K9/24
CPC分类号： A61K31/485
摘要： A composition for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The composition comprises methylnaltrexone or another quaternary derivative of noroxymorphone administered to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
摘要翻译： 公开了用于预防或治疗阿片样物质诱导的副作用，抑制胃肠蠕动的组合物。 该组合物包含甲基纳曲酮或在给予阿片样物体之前向患者施用的诺莫诺莫司的另一季衍生物，或者在施用阿片样物质引起的副作用开始后，其中甲醛纳曲酮或季衍生物以肠溶包衣形式口服给药 。
-
公开(公告)号：US5023083A
公开(公告)日：1991-06-11
申请号：US464598
申请日：1990-01-12
申请人： William Drell
发明人： William Drell
IPC分类号： A61K9/50
CPC分类号： A61K31/70 , A61K9/5078
摘要： A method for treating azaribine-responsive diseases in patient's who exhibit severe pyridoxal phosphate depletion following the oral administration of azaribine comprises first encapsulating azaribine in a film-forming substance which is selectively soluble in the digestive juice of the intestines. The encapsulated azaribine is then orally administered to the patient in an amount effective for the treatment of the disease, preferably in an amount to provide from about 1.5 to about 15 grams of azaribine per square meter of patient body surface area per day.
摘要翻译： 在口服给药阿扎利班之后，在患者中显示出严重的吡哆醛磷酸盐耗竭的患者中的阿扎利班反应性疾病的治疗方法包括首先在可肠溶消化液中的成膜物质中包封阿扎利班。 然后将包封的阿扎利班以有效治疗疾病的量口服施用给患者，优选以每平方米每天每平方米患者体表面积提供约1.5至约15克阿扎利班的量。
-
10.发明授权Method for administration of azauridine and pyridoxine for the treatment of rheumatoid arthritis 失效用于治疗类风湿性关节炎的azauridine和吡哆醇的给药方法
公开(公告)号：US5389617A
公开(公告)日：1995-02-14
申请号：US152255
申请日：1993-11-12
申请人： William Drell
发明人： William Drell
CPC分类号： A61K31/70 , Y10S514/825 , Y10S514/922
摘要： A method for treating patients with rheumatoid arthritis comprises administering azaribine to the patient at a dosage level of 10 to 50 mg/kg/day for an initial period of from about 1 to about 3 weeks and then administering azaribine to the patient at dosage levels of at least 50 mg/kg/day and preferably at least 100 mg/kg/day.
摘要翻译： 用于治疗类风湿性关节炎患者的方法包括以10至50mg / kg /天的剂量水平向患者施用阿扎利班，初始时间为约1至约3周，然后以剂量水平施用阿扎利班 至少50mg / kg /天，优选至少100mg / kg /天。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.027 秒)